Left ventricular assist devices as destination therapy for end-stage heart failure

被引：14

作者：

Stevenson L.W. ^{[1
]}

机构：

[1] Brigham and Women's Hospital, Cardiovascular Division, Boston, MA 02115

来源：

Current Treatment Options in Cardiovascular Medicine | 2004年 / 6卷 / 6期

关键词：

Left Ventricular Assist Device; Cardiac Transplantation; Mechanical Circulatory Support; Destination Therapy; Left Ventricular Assist Device Implantation;

D O I：

10.1007/s11936-004-0004-9

中图分类号：

学科分类号：

摘要：

In the therapy of advanced heart failure, left ventricular assist devices represent an exciting new option. The role of mechanical circulatory support is currently limited predominantly by factors related to device durability. The population for whom mechanical circulatory support can be considered as permanent therapy is defined by those for whom improvement in survival and clinical function is expected from current devices. Reported device survival in the range of 50% at 1 year limits the present candidate population to those with greater than 50% mortality at 1 year, who are not eligible for cardiac transplantation, after which survival is 50% at 10 years. Even as we learn to identify these patients who are "sick enough" to warrant device placement and yet "well enough" to survive surgery, the devices and surgical techniques are evolving so that the outcomes are improving and the candidate population is expanding. Copyright © 2004 by Current Science Inc.

引用

页码：471 / 479

页数：8

共 19 条

[1]

Stevenson L.W., Kormos R.L., Mechanical cardiac support 2000: Current applications and future trial design, J. Am. Coll. Cardiol., 37, pp. 340-370, (2001)

[2]

Frazier O.H., Rose E.A., Oz M.C., Et al., Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation, J. Thorac. Cardiovasc. Surg., 122, pp. 1186-1195, (2001)

[3]

Taylor D.O., Edwards L.B., Mohacsi P.J., Et al., The registry of the International Society for Heart and Lung Transplantation: Twentieth official adult heart transplant report - 2003, J. Heart Lung Transplant, 22, pp. 616-624, (2003)

[4]

Rose E.A., Gelijns A.C., Moskowitz A.J., Et al., Long-term use of a left ventricular assist device for end-stage heart failure, N. Engl. J. Med., 345, pp. 1435-1443, (2001)

[5]

Stevenson L.W., Rose E.A., Left ventricular assist devices: Bridges to transplantation, recovery, and destination for whom?, Circulation, 108, pp. 3059-3063, (2003)

[6]

Miller L.W., Listing criteria for cardiac transplantation: Results of an American Society of Transplant Physicians-National Institutes of Health conference, Transplantation, 66, pp. 947-951, (1998)

[7]

Hunt S.A., Baker D.W., Chin M.H., Et al., ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary, J. Am. Coll. Cardiol., 38, pp. 2101-2113, (2001)

[8]

Nohria A., Lewis E., Stevenson L.W., Medical management of advanced heart failure, JAMA, 287, pp. 628-640, (2002)

[9]

Rose E.A., Moskowitz A.J., Packer M., Et al., The REMATCH trial: Rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure, Ann. Thorac. Surg., 67, pp. 723-730, (1999)

[10]

Deng M.C., Young J.B., Stevenson L.W., Et al., Destination mechanical circulatory support: Proposal for clinical standards, J. Heart Lung Transplant, 22, pp. 365-369, (2003)

← 1 2 →